Home LiteratureArticle Details
PMID: 8970991 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene.

Journal of virology ·Vol. 70 ·No. 12 ·1996-12-00 ·Pages 8653-9

Fries KL, Miller WE, Raab-Traub N

Abstract

Two Epstein-Barr virus (EBV)-associated malignancies, nasopharyngeal carcinoma and posttransplant lymphoma, rarely have mutations in the p53 tumor suppressor gene, suggesting that a viral protein interferes with p53 function. The EBV oncogene, LMP1, induces expression of the cellular antiapoptotic genes bcl-2 and A20 and could in this way interfere with p53-mediated apoptosis. Two derivatives of the p53-null epithelial cell line H1299 were prepared, one of which (H1299-p53) stably expressed a temperature-sensitive (ts) p53 protein, and another (H1299-p53+LMP1) which stably expressed both ts-p53 and latent membrane protein 1 (LMP1). At the permissive temperature, the p53 protein in the H1299-p53 cell line transcriptionally activated two of its target genes, the cyclin-dependent kinase inhibitor p21 and the mdm2 gene product, in an LMP1-independent manner. Upon serum withdrawal at the permissive temperature, p53-mediated apoptosis was induced in 50 to 60% of the cells. In the H1299-p53 cell line which stably expressed LMP1, however, only 20 to 25% of the cells underwent apoptosis. While stable expression of LMP1 did not affect levels of bcl-2 family members in these cells, it did induce expression of A20. Stable expression of A20 in the H1299-p53 cell line inhibited p53-mediated apoptosis equivalent to inhibition by LMP1. The induction of A20 may underlie the ability of LMP1 to protect EBV-infected epithelial cells from p53-mediated apoptosis.

MeSH Terms
Animals Apoptosis/physiology Cell Line Cysteine Endopeptidases DNA-Binding Proteins Herpesvirus 4, Human/metabolism Humans Intracellular Signaling Peptides and Proteins Mice Mutagenesis Nuclear Proteins Proteins/genetics,metabolism Proto-Oncogene Proteins/metabolism Proto-Oncogene Proteins c-bcl-2/metabolism Proto-Oncogene Proteins c-mdm2 Proto-Oncogene Proteins p21(ras)/metabolism Signal Transduction/physiology Tumor Cells, Cultured Tumor Necrosis Factor alpha-Induced Protein 3 Tumor Necrosis Factor-alpha/genetics,metabolism Tumor Suppressor Protein p53/genetics,metabolism Viral Matrix Proteins/genetics,metabolism bcl-X Protein
Chemicals
BCL2L1 protein, human Bcl2l1 protein, mouse DNA-Binding Proteins EBV-associated membrane antigen, Epstein-Barr virus Intracellular Signaling Peptides and Proteins Nuclear Proteins Proteins Proto-Oncogene Proteins Proto-Oncogene Proteins c-bcl-2 Tumor Necrosis Factor-alpha Tumor Suppressor Protein p53 Viral Matrix Proteins bcl-X Protein MDM2 protein, human Mdm2 protein, mouse Proto-Oncogene Proteins c-mdm2 TNFAIP3 protein, human Tumor Necrosis Factor alpha-Induced Protein 3 Cysteine Endopeptidases Tnfaip3 protein, mouse HRAS protein, human Proto-Oncogene Proteins p21(ras)
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Fries K L
Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, 27599-7295, USA.
Miller W E
Raab-Traub N
References (85)
85 references, click to expand
  1. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers.
    J Virol. 1994 Sep;68(9):5602-12 PMID: 7520093
  2. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor.
    Cell. 1994 Aug 26;78(4):681-92 PMID: 8069916
  3. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
    J Virol. 1990 May;64(5):2309-18 PMID: 2157887
  4. Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals.
    Transplantation. 1990 May;49(5):944-53 PMID: 2159663
  5. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.
    Cell. 1990 Aug 24;62(4):671-80 PMID: 2143698
  6. Novel transcription from the Epstein-Barr virus terminal EcoRI fragment, DIJhet, in a nasopharyngeal carcinoma.
    J Virol. 1990 Oct;64(10):4948-56 PMID: 2168978
  7. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.
    Cell. 1990 Dec 21;63(6):1129-36 PMID: 2175676
  8. Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients.
    Int J Cancer. 1991 Jan 21;47(2):188-92 PMID: 1846349
  9. Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo.
    J Virol. 1991 Nov;65(11):6252-9 PMID: 1656092
  10. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene.
    Oncogene. 1991 Oct;6(10):1791-7 PMID: 1923504
  11. Participation of p53 protein in the cellular response to DNA damage.
    Cancer Res. 1991 Dec 1;51(23 Pt 1):6304-11 PMID: 1933891
  12. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
    Oncogene. 1992 Jan;7(1):171-80 PMID: 1311061
  13. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma.
    J Virol. 1992 May;66(5):3257-62 PMID: 1313931
  14. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.
    Nature. 1992 May 7;357(6373):82-5 PMID: 1533443
  15. Alterations of the p53 gene in nasopharyngeal carcinoma.
    J Virol. 1992 Jun;66(6):3768-75 PMID: 1349927
  16. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line.
    Proc Natl Acad Sci U S A. 1992 May 15;89(10):4495-9 PMID: 1584781
  17. Apoptosis and programmed cell death in immunity.
    Annu Rev Immunol. 1992;10:267-93 PMID: 1590988
  18. Wild-type p53 activates transcription in vitro.
    Nature. 1992 Jul 2;358(6381):83-6 PMID: 1614538
  19. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity.
    J Biol Chem. 1992 Jun 25;267(18):12424-7 PMID: 1618749
  20. The status of the p53 gene in human papilloma virus positive or negative cervical carcinoma cell lines.
    Carcinogenesis. 1992 Jul;13(7):1273-5 PMID: 1322252
  21. Two TNF receptors.
    Immunol Today. 1992 May;13(5):151-3 PMID: 1322675
  22. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia.
    Cancer Res. 1994 Oct 1;54(19):5054-8 PMID: 7923116
  23. Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53.
    Genes Dev. 1994 Jun 1;8(11):1300-10 PMID: 7986270
  24. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways.
    Oncogene. 1994 Dec;9(12):3407-15 PMID: 7970699
  25. A novel RING finger protein interacts with the cytoplasmic domain of CD40.
    J Biol Chem. 1994 Dec 2;269(48):30069-72 PMID: 7527023
  26. Structural analyses of the Epstein-Barr virus BamHI A transcripts.
    J Virol. 1995 Feb;69(2):1132-41 PMID: 7815492
  27. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family.
    Cell. 1995 Feb 10;80(3):389-99 PMID: 7859281
  28. Involvement of CRAF1, a relative of TRAF, in CD40 signaling.
    Science. 1995 Mar 10;267(5203):1494-8 PMID: 7533327
  29. Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53.
    EMBO J. 1995 Apr 3;14(7):1382-91 PMID: 7729416
  30. Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis.
    J Biol Chem. 1995 May 26;270(21):12343-6 PMID: 7539000
  31. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor.
    J Virol. 1995 Jul;69(7):4390-8 PMID: 7769701
  32. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-kappa B/Rel family proteins.
    J Virol. 1995 Jul;69(7):4572-6 PMID: 7769726
  33. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40.
    Science. 1995 Sep 8;269(5229):1424-7 PMID: 7544915
  34. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control.
    Cell. 1995 Aug 25;82(4):675-84 PMID: 7664346
  35. Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells.
    Am J Pathol. 1995 Oct;147(4):1152-60 PMID: 7573360
  36. The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest.
    Oncogene. 1995 Sep 21;11(6):1027-31 PMID: 7566960
  37. A20 zinc finger protein inhibits TNF and IL-1 signaling.
    J Immunol. 1996 Feb 1;156(3):1166-73 PMID: 8557994
  38. Biological activities of p53 mutants in Burkitt's lymphoma cells.
    J Gen Virol. 1993 May;74 ( Pt 5):803-10 PMID: 8492087
  39. p53 mutations in human cancers.
    Science. 1991 Jul 5;253(5015):49-53 PMID: 1905840
  40. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death.
    Cell. 1991 Jun 28;65(7):1107-15 PMID: 1648447
  41. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6.
    Nature. 1991 Jul 25;352(6333):345-7 PMID: 1852210
  42. p53 is frequently mutated in Burkitt's lymphoma cell lines.
    EMBO J. 1991 Oct;10(10):2879-87 PMID: 1915267
  43. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx.
    Nature. 1970 Dec 12;228(5276):1056-8 PMID: 4320657
  44. Nasopharyngeal carcinoma. X. Presence of epstein-barr genomes in separated epithelial cells of tumours in patients from Singapore, Tunisia and Kenya.
    Int J Cancer. 1975 Jul 15;16(1):7-15 PMID: 170215
  45. DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative.
    Cell. 1980 Nov;22(1 Pt 1):257-67 PMID: 6253079
  46. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation.
    N Engl J Med. 1982 Apr 15;306(15):913-8 PMID: 6278307
  47. Epstein-Barr virus markers in a series of Burkitt's lymphomas from the West Nile District, Uganda.
    Eur J Cancer Clin Oncol. 1983 Oct;19(10):1393-404 PMID: 6315443
  48. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells.
    Cell. 1985 Dec;43(3 Pt 2):831-40 PMID: 3000618
  49. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA.
    Int J Cancer. 1987 Jan 15;39(1):25-9 PMID: 3025109
  50. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.
    EMBO J. 1987 Sep;6(9):2743-51 PMID: 2824192
  51. Epstein-Barr virus gene expression in nasopharyngeal carcinoma.
    J Gen Virol. 1988 May;69 ( Pt 5):1051-65 PMID: 2836550
  52. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus.
    Oncogene. 1988 May;2(5):461-7 PMID: 2836780
  53. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma.
    Int J Cancer. 1988 Sep 15;42(3):329-38 PMID: 2843473
  54. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases.
    J Infect Dis. 1989 Oct;160(4):589-98 PMID: 2551973
  55. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.
    N Engl J Med. 1989 Oct 19;321(16):1080-5 PMID: 2552313
  56. EBV gene expression in an NPC-related tumour.
    EMBO J. 1989 Sep;8(9):2639-51 PMID: 2479554
  57. Mutations in the p53 gene occur in diverse human tumour types.
    Nature. 1989 Dec 7;342(6250):705-8 PMID: 2531845
  58. Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin.
    J Biol Chem. 1990 Feb 15;265(5):2973-8 PMID: 2406243
  59. Association of human papillomavirus types 16 and 18 E6 proteins with p53.
    Science. 1990 Apr 6;248(4951):76-9 PMID: 2157286
  60. Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
    Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7491-5 PMID: 1323840
  61. Absence of p53 gene mutations in primary nasopharyngeal carcinomas.
    Cancer Res. 1992 Sep 1;52(17):4787-90 PMID: 1511442
  62. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity.
    J Virol. 1992 Nov;66(11):6496-501 PMID: 1404600
  63. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.
    Cell. 1992 Nov 13;71(4):587-97 PMID: 1423616
  64. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B.
    J Biol Chem. 1992 Dec 5;267(34):24157-60 PMID: 1332946
  65. Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma.
    Int J Cancer. 1993 Jan 2;53(1):29-35 PMID: 8380056
  66. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein.
    EMBO J. 1992 Dec;11(13):5013-20 PMID: 1464323
  67. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts.
    J Virol. 1993 Mar;67(3):1638-46 PMID: 8382313
  68. mdm2 expression is induced by wild type p53 activity.
    EMBO J. 1993 Feb;12(2):461-8 PMID: 8440237
  69. p53 mutation in human nasopharyngeal carcinomas.
    Anticancer Res. 1992 Nov-Dec;12(6B):1957-63 PMID: 1295443
  70. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis.
    Genes Dev. 1993 Apr;7(4):535-45 PMID: 8384579
  71. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B.
    Genes Dev. 1993 Apr;7(4):546-54 PMID: 8384580
  72. p53 is required for radiation-induced apoptosis in mouse thymocytes.
    Nature. 1993 Apr 29;362(6423):847-9 PMID: 8479522
  73. Thymocyte apoptosis induced by p53-dependent and independent pathways.
    Nature. 1993 Apr 29;362(6423):849-52 PMID: 8479523
  74. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation.
    Genes Dev. 1993 Aug;7(8):1572-83 PMID: 8101826
  75. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.
    Cell. 1993 Aug 27;74(4):597-608 PMID: 8358789
  76. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.
    Cell. 1993 Aug 27;74(4):609-19 PMID: 8358790
  77. SV40 T antigen abrogates p53-mediated transcriptional activity.
    Oncogene. 1993 Oct;8(10):2805-12 PMID: 8378089
  78. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.
    Cell. 1993 Sep 24;74(6):957-67 PMID: 8402885
  79. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation.
    Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9150-4 PMID: 8415670
  80. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
    Cell. 1993 Nov 19;75(4):805-16 PMID: 8242751
  81. WAF1, a potential mediator of p53 tumor suppression.
    Cell. 1993 Nov 19;75(4):817-25 PMID: 8242752
  82. p21 is a universal inhibitor of cyclin kinases.
    Nature. 1993 Dec 16;366(6456):701-4 PMID: 8259214
  83. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit.
    Nature. 1993 Dec 16;366(6456):707-10 PMID: 8259216
  84. Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphomas.
    J Virol. 1994 Mar;68(3):1309-15 PMID: 8107196
  85. DNA damage, oncogenesis and the p53 tumour-suppressor gene.
    Mutat Res. 1994 Jun 1;307(2):573-81 PMID: 7514730
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1996-12-00
Pages
8653-9
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC190959
Subset
IM
Grants
NCI NIH HHS · CA 19014 · United States
NCI NIH HHS · CA 32979 · United States
NIDCR NIH HHS · DE 11644 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]